IL302678A - History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia and cancer - Google Patents
History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia and cancerInfo
- Publication number
- IL302678A IL302678A IL302678A IL30267823A IL302678A IL 302678 A IL302678 A IL 302678A IL 302678 A IL302678 A IL 302678A IL 30267823 A IL30267823 A IL 30267823A IL 302678 A IL302678 A IL 302678A
- Authority
- IL
- Israel
- Prior art keywords
- 12alkyl
- independently
- compound
- pharmaceutically acceptable
- foregoing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112609P | 2020-11-11 | 2020-11-11 | |
| PCT/US2020/062627 WO2022103411A1 (en) | 2020-11-11 | 2020-11-30 | 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302678A true IL302678A (en) | 2023-07-01 |
Family
ID=73839136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302678A IL302678A (en) | 2020-11-11 | 2020-11-30 | History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxy-N-(benzyl)pyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia and cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230391766A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4244218B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7654075B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102992222B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116783183B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020476996A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3197092A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302678A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023005305A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022103411A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4244219B1 (en) | 2020-11-11 | 2026-06-03 | Genentech, Inc. | 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia |
| WO2023220237A1 (en) * | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Benzothiazole compounds as vhl ligands |
| WO2025162250A1 (zh) * | 2024-02-04 | 2025-08-07 | 贝达药业股份有限公司 | 取代的三环化合物及其用途 |
| WO2025228305A1 (zh) * | 2024-04-28 | 2025-11-06 | 中国科学院上海药物研究所 | 一种蛋白降解剂缀合物及其偶联物 |
| WO2026012475A1 (en) * | 2024-07-12 | 2026-01-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Vhl ligands and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2013106646A2 (en) * | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| GB2554071A (en) * | 2016-09-14 | 2018-03-28 | Univ Dundee | Small molecules |
| CN110573507B (zh) * | 2017-04-14 | 2023-11-14 | 邓迪大学 | 小分子 |
| US11547759B2 (en) * | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
-
2020
- 2020-11-30 IL IL302678A patent/IL302678A/en unknown
- 2020-11-30 JP JP2023528057A patent/JP7654075B2/ja active Active
- 2020-11-30 MX MX2023005305A patent/MX2023005305A/es unknown
- 2020-11-30 KR KR1020237018547A patent/KR102992222B1/ko active Active
- 2020-11-30 AU AU2020476996A patent/AU2020476996A1/en active Pending
- 2020-11-30 WO PCT/US2020/062627 patent/WO2022103411A1/en not_active Ceased
- 2020-11-30 CN CN202080108318.5A patent/CN116783183B/zh active Active
- 2020-11-30 CA CA3197092A patent/CA3197092A1/en active Pending
- 2020-11-30 EP EP20825085.2A patent/EP4244218B1/en active Active
-
2023
- 2023-05-09 US US18/195,134 patent/US20230391766A1/en active Pending
-
2025
- 2025-01-23 JP JP2025009859A patent/JP2025063287A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230391766A1 (en) | 2023-12-07 |
| JP2023549187A (ja) | 2023-11-22 |
| KR102992222B1 (ko) | 2026-07-16 |
| CA3197092A1 (en) | 2022-05-19 |
| EP4244218A1 (en) | 2023-09-20 |
| CN116783183B (zh) | 2026-03-20 |
| JP7654075B2 (ja) | 2025-03-31 |
| EP4244218C0 (en) | 2026-07-08 |
| EP4244218B1 (en) | 2026-07-08 |
| AU2020476996A1 (en) | 2023-06-29 |
| WO2022103411A1 (en) | 2022-05-19 |
| CN116783183A (zh) | 2023-09-19 |
| KR20230106637A (ko) | 2023-07-13 |
| JP2025063287A (ja) | 2025-04-15 |
| MX2023005305A (es) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7654075B2 (ja) | 貧血およびがんの処置のためのvhl阻害剤としての1-(2-(4-シクロプロピル-1h-1,2,3-トリアゾール-1-イル)アセチル)-4-ヒドロキシ-n-(ベンジル)ピロリジンe-2-カルボキサミド誘導体 | |
| KR101686685B1 (ko) | 피라졸로피리미딘 jak 억제제 화합물 및 방법 | |
| US9573943B2 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| IL272016B2 (en) | Pyrrolidine derivatives and their use as tlr7/8 antagonists | |
| IL258081B2 (en) | Benzimidazole history and their use | |
| CN107849055A (zh) | 用作irak1/4抑制剂的大环化合物及其用途 | |
| KR20130086520A (ko) | 스피로시클릭 화합물 및 이들의 치료제 및 진단 프로브로서 용도 | |
| AU2017348826A1 (en) | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | |
| CN107428765A (zh) | 用作irak抑制剂的哒嗪酮类大环化合物及其用途 | |
| CN108137559A (zh) | 用作btk抑制剂的嘧啶衍生物及其用途 | |
| CN111971278A (zh) | 用作irak抑制剂的喹啉化合物及其用途 | |
| WO2024152710A1 (zh) | 谷氨酰胺环化酶抑制剂及其应用 | |
| KR20130118731A (ko) | 항증식성 질환 치료에 사용하기 위한 pi3k 억제제로서 피페라지노트리아진 | |
| US20250129063A1 (en) | Benzothiazole compounds as vhl ligands | |
| IL302677A (en) | History of 1-(2-(4-cyclopropyl-1H-3,2,1-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxamide as VHL inhibitors for the treatment of anemia | |
| CA3256395A1 (fr) | Procédé de test d'audiométrie vocale mettant en oeuvre une reconnaissance vocale et dispositif électronique associé | |
| JP2019510054A (ja) | シクロフィリンの阻害のための化合物及びその使用 | |
| TW202508585A (zh) | 用於治療紫質症(porphyria)之醯胺吡啶并[3,4-B]吲哚-1,4-二酮化合物 | |
| CN121226368A (zh) | Ripk1抑制剂及其医药用途 | |
| HK40092810A (en) | 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidine-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer | |
| WO2026037254A1 (zh) | 作为mrgprx2拮抗剂的化合物 |